A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats
- 3 July 2002
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 40 (1), 175-181
- https://doi.org/10.1016/s0735-1097(02)01911-3
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary HypertensionChest, 1999
- Recognition and management of pulmonary hypertension.Drugs, 1998
- Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol InfusionJournal of the American College of Cardiology, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- The Role of Endothelium in Cardiovascular Homeostasis and DiseasesJournal of Cardiovascular Pharmacology, 1993
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984
- Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.Circulation, 1982
- PROSTACYCLIN AND PROSTAGLANDIN E1 FOR SEVERE IDIOPATHIC PULMONARY ARTERY HYPERTENSIONThe Lancet, 1980